M. Manning

M. Manning, W. Sawyer, C. Pang, 1979, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Discovery of novel selective hypotensive vasopressin peptides that exhibit little or no functional interactions with known oxytocin/vasopressin receptors

S. Stoev, M. Manning, W. Y. Chan, 1998, British journal of pharmacology.

Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptors.

N. Cotte, E. Tribollet, J. Dreifuss, 1997, European journal of pharmacology.

Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an "easy guide" to receptor pharmacology.

G. Guillon, M. Manning, B. Chini, 2008, Progress in brain research.

Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges.

M. Manning, B. Chini, 2007, Biochemical Society transactions.

Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals.

G. Griebel, J. Simiand, G. Guillon, 2003, Stress.

Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis.

A. F. Muller, G. Guillon, M. Manning, 1986, Molecular pharmacology.

Vasopressin in the rat with partial nephrectomy-salt hypertension.

M. Manning, R. Shade, L. Share, 1981, Clinical and experimental hypertension.

(1-(β-MERCAPTO-β,β-CYCLOPENTAMETHYLENEPROPIONIC ACID),4-VALINE, 8-D-ARGININE)VASOPRESSIN, A POTENT AND SELECTIVE INHIBITOR OF THE VASOPRESSOR RESPONSE TO ARGININE-VASOPRESSIN

M. Manning, W. Sawyer, J. Lowbridge, 1978 .

[1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),4-valine,-8-D-arginine]vasopressin, a potent and selective inhibitor of the vasopressor response to arginine-vasopressin.

M. Manning, W. Sawyer, J. Lowbridge, 1978, Journal of medicinal chemistry.

Vasopressin-binding sites in the pig pituitary gland: competition by novel vasopressin antagonists suggests the existence of an unusual receptor subtype in the anterior lobe.

Y. Arsenijévic, E. Tribollet, M. Dubois‐Dauphin, 1994, Journal of Endocrinology.

Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.

S. Stoev, M. Manning, A. Misicka, 1992, Journal of medicinal chemistry.

A radioiodinated linear vasopressin antagonist: A ligand with high affinity and specificity for V1a receptors

M. Manning, S. Audigier, C. Barberis, 1991, FEBS letters.

Novel selective hypotensive vasopressin peptides: cardiovascular and structure-activity-relationship studies.

S. Stoev, M. Manning, R. Levi, 2001, European journal of pharmacology.

Control of Social Withdrawal of Mice Deficient for the Autism Gene Magel2 by Restoration of Vasopressin-Oxytocin Dialogue in Septum

G. Guillon, M. Manning, F. Muscatelli, 2019, bioRxiv.

Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

G. Guillon, S. Stoev, M. Manning, 2008, Progress in brain research.

The development of vasopressin antagonists.

M. Manning, W. H. Sawyer, 1984, Federation proceedings.

Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.

M. Manning, A. Olma, W. Sawyer, 1989, Journal of medicinal chemistry.

Selective Agonists and Antagonists of Vasopressin

M. Manning, W. Sawyer, K. Bańkowski, 1987 .

Design of potent and selective in vivo antagonists of the neurohypophysial peptides.

M. Manning, W. H. Sawyer, 1983, Progress in brain research.

Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and antidiuretic actions: effects of highly potent analogues and competitive inhibitors.

G. Guillon, M. Manning, W. Sawyer, 1978, Molecular pharmacology.

Design of potent antagonists of the vasopressor response to arginine-vasopressin.

M. Manning, W. Sawyer, K. Bańkowski, 1978, Journal of medicinal chemistry.

Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.

M. Manning, W. Sawyer, L. Balaspiri, 1976, Journal of medicinal chemistry.

Solid-phase synthesis and some pharmacological properties of 4-threonine analogs of vasopressins and vasotocin and of arginine-vasopressin and arginine-vasotocin.

M. Manning, W. H. Sawyer, E. Coy, 1973, Journal of medicinal chemistry.

Synthetic analogs of oxytocin and the vasopressins.

M. Manning, W. H. Sawyer, 1973, Annual review of pharmacology.

Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-isoleucine,4- valine]arginine-vasopressin at position 4.

M. Manning, A. Misicka, A. Olma, 1984, Journal of medicinal chemistry.

Design of potent and selective antagonists of the vasopressor responses to arginine-vasopressin.

M. Manning, W. Sawyer, J. Seto, 1982, Journal of medicinal chemistry.

Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin.

M. Manning, A. Olma, W. Sawyer, 1982, Journal of medicinal chemistry.

Neurohypophysial peptides design of tissue-specific agonists and antagonists

M. Manning, W. H. Sawyer, Z. Grzonka, 1981, Molecular and Cellular Endocrinology.

Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

G. Guillon, S. Stoev, M. Manning, 2012, Journal of neuroendocrinology.

Synthesis by the Merrifield method of a protected nonapeptide amide with the amino acid sequence of oxytocin.

M. Manning, 1968, Journal of the American Chemical Society.

Synthesis and some pharmacological properties of [4-homoserine]oxytocin.

M. Manning, W. H. Sawyer, J. Haldar, 1977, Journal of medicinal chemistry.

Solid-phase syntheis and some pharmacological properties of [8-phenylalanine]-oxytocin.

M. Manning, W. H. Sawyer, J. W. Baxter, 1969, Biochemistry.

125I‐d(CH2)5[Tyr(Me)2,Tyr(NH2)9]AVP: Iodination and binding characteristics of a vasopressin receptor ligand

M. Manning, C. Barberis, J. Elands, 1988, FEBS letters.

[1-(L-2-hydroxy-3-mercaptopropanoic acid)] analogues of arginine-vasopressin, [8-D-arginine]vasopressin, and [4-valine,8-D-arginine]vasopressin.

M. Manning, W. Sawyer, J. Lowbridge, 1977, Journal of medicinal chemistry.

534. The preparation and some reactions of 4-formyl-l-phenylpyrazoles

M. Manning, I. Finar, 1961 .

Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors.

G. Guillon, S. Stoev, M. Manning, 2007, Endocrinology.

Design and synthesis of potent, highly selective vasopressin hypotensive agonists

S. Stoev, M. Manning, H. Szeto, 2006, Journal of peptide science : an official publication of the European Peptide Society.

DISCIOVERY AND DESIGN OF NOVEL VASOPFESIN HYE'OTENSIW PEPTIDE AGONISTS

M. Manning, S. Stoeva, 1999 .

Discovery and design of novel vasopressin hypotensive peptide agonists.

S. Stoev, M. Manning, W. Y. Chan, 1999, Journal of receptor and signal transduction research.

Vasopressin and oxytocin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

G. Gimpl, J. Verbalis, D. Bichet, 2019, IUPHAR/BPS Guide to Pharmacology CITE.

A convenient method for O-alkylation of N-substituted tyrosines using a crown ether

M. Manning, A. Kolodziejczyk, 1981 .

An exploration of the effects of L‐ and D‐tetrahydroisoquinoline‐3‐carboxylic acid substitutions at positions 2,3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin

S. Stoev, M. Manning, W. Kliś, 1995, Journal of peptide science : an official publication of the European Peptide Society.

C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.

M. Manning, A. Misicka, A. Olma, 1987, Journal of medicinal chemistry.

No requirement of cyclic conformation of antagonists in binding to vasopressin receptors

M. Manning, W. H. Sawyer, A. Olma, 1987, Nature.

Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxy[Thr4, Gly7]oxytocin), and [7-Glycine]oxytocin, peptides with high oxytocic-antidiuretic selectivity.

M. Manning, W. H. Sawyer, J. Lowbridge, 1977, Journal of Medicinal Chemistry.

Design and synthesis of potent in vivo antagonists of oxytocin.

M. Manning, W. Sawyer, J. Seto, 2009, International journal of peptide and protein research.

125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT: a selective oxytocin receptor ligand.

E. Tribollet, J. Dreifuss, M. Manning, 1988, European journal of pharmacology.

Potent V2 vasopressin antagonists with structural changes at their C-terminals

S. Stoev, M. Manning, A. Misicka, 1988, Peptides.

The design of effective in vivo antagonists of rat uterus and milk ejection responses to oxytocin.

M. Manning, A. Turan, W. Sawyer, 1980, Endocrinology.

Receptor-specific antagonists of vasopressin and oxytocin. A current perspective.

S. Stoev, M. Manning, W. Sawyer, 1993, Annals of the New York Academy of Sciences.

A fraction resembling oxytocin from Squalus acanthias: pharmacological comparisons with synthetic peptides.

M. Manning, W. Sawyer, E. Heinicke, 1970, General and Comparative Endocrinology.

Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.

M. Manning, W. Y. Chan, L. Cheng, 1996, The Journal of pharmacology and experimental therapeutics.

Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban

S. Stoev, M. Manning, B. Mouillac, 2005, Journal of peptide science : an official publication of the European Peptide Society.

Potent antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-D- phenylalanine,4-valine]arginine-vasopressin at position 4.

M. Manning, A. Olma, W. Sawyer, 1983, Journal of medicinal chemistry.

Invertebrate neuropeptides resembling vasotocin and some analogues: Synthesis and pharmacological properties

M. Manning, W. H. Sawyer, M. Kruszynski, 1990, Experientia.

Structural changes in the arginine vasopressin molecule that enhance antidiuretic activity and specificity.

M. Manning, W. Sawyer, L. Balaspiri, 1974, Endocrinology.

Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone.

M. Manning, W. H. Sawyer, P. Pang, 1981, Science.

POTENT AND SELECTIVE ANTAGONISTS OF THE ANTIDIURETIC RESPONSES TO ARGININE-VASOPRESSIN BASED ON MODIFICATIONS OF (1-(β-MERCAPTO-β,β-PENTAMETHYLENEPROPIONIC ACID), 2-D-ISOLEUCINE, 4-VALINE)ARGININE-VASOPRESSIN AT POSITION 4

M. Manning, A. Misicka, A. Olma, 1984 .

Potent Antagonists of the Antidiuretic Responses to Arginine-Vasopressin Based on Modifications of [1(β-Mercapto-β,β-cyclopentamethylenepropionic Acid)2-D-phenylalanine,4-valine]arginine-vasopressin at Position 4.

M. Manning, A. Olma, W. Sawyer, 1984 .

The Role of the Merrifield Solid Phase Method in the Discovery and Exploration of a New Class of Selective Vasopressin Hypotensive Agonists

S. Stoev, M. Manning, H. Szeto, 2007, International Journal of Peptide Research and Therapeutics.

Design of More Potent, Radioiodinatable and Fluorescent Vasopressin Hypotensive Peptide Agonists

S. Stoev, M. Manning, W. Y. Chan, 2001 .

Synthesis and structure–activity investigation of novel vasopressin hypotensive peptide agonists

S. Stoev, M. Manning, W. Y. Chan, 1999, Journal of peptide science : an official publication of the European Peptide Society.

Solid phase synthesis of (1-deamino,4-valine)-8-D-arginine-vasopressin (DVDAVP), a highly potent and specific antidiuretic agent possessing protracted effects.

M. Manning, W. Sawyer, L. Balaspiri, 1973, Journal of medicinal chemistry.

Impact of the Merrifield solid phase method on the design and synthesis of selective agonists and antagonists of oxytocin and vasopressin: A historical perspective

M. Manning, 2008, Biopolymers.

Position 4 analogues of [deamino‐Cys1] arginine vasopressin exhibit striking species differences for human and rat V2/V1b receptor selectivity

G. Guillon, S. Stoev, M. Manning, 2006, Journal of peptide science : an official publication of the European Peptide Society.

Cyclic and linear vasopressin V1 and V1/V2 antagonists containing arginine in the 4-position

M. Manning, A. Misicka, W. H. Sawyer, 1991, Experientia.

An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally‐restricted, polar and charged amino acids

S. Stoev, M. Manning, A. Olma, 1999, Journal of peptide science : an official publication of the European Peptide Society.

Novel approach to the design of synthetic radioiodinated linear V1A receptor antagonists of vasopressin.

M. Manning, C. Barberis, J. Elands, 2009, International journal of peptide and protein research.

Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressin.

M. Manning, A. Olma, W. Sawyer, 2009, International journal of peptide and protein research.

Probing the molecular basis of antidiuretic specificity and duration of action with synthetic peptides

M. Manning, W. H. Sawyer, L. Balaspiri, 1974, FEBS letters.

SOLID PHASE SYNTHESIS OF (1-DEAMINO, 4-VALINE)-8-D-ARGININE-VASOPRESSIN (DVDAVP), A HIGHLY POTENT AND SPECIFIC ANTIDIURETIC AGENT POSSESSING PROTACTED EFFECTS

M. Manning, W. Sawyer, L. Balaspiri, 1973 .

An investigation of position 3 in arginine vasopressin (AVP)

S. Stoev, M. Manning, A. Olma, 2002 .

Position Three in Vasopressin Antagonist Tolerates Conformationally Restricted and Aromatic Amino Acid Substitutions: A Striking Contrast with Vasopressin Agonists

S. Stoev, M. Manning, A. Olma, 1997, Journal of peptide science : an official publication of the European Peptide Society.

Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin.

M. Manning, W. H. Sawyer, Wilbur H. Sawyer, 1993, Journal of receptor research.

Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor.

J Hoflack, S. Trumpp-Kallmeyer, M. Manning, 1995, The EMBO journal.

Molecular pharmacology of AVP and OT receptors and therapeutic potential

E. Tribollet, G. Guillon, R. Seyer, 1999 .

4-β-Alanine-oxytocin: An Oxytocin Analog Containing a Twenty-one-membered Disulfide Ring*

M. Manning, V. Vigneaud, 1965 .

SYNTHESIS AND SOME PHARMACOLOGICAL PROPERTIES OF DEAMINO(4-THREONINE,8-D-ARGININE)VASOPRESSIN AND DEAMINO(8-D-ARGININE)VASOPRESSIN, HIGHLY POTENT AND SPECIFIC ANTIDIURETIC PEPTIDES, AND (8-D-ARGININE)VASOPRESSIN AND DEAMINO-ARGININE-V

M. Manning, W. Sawyer, L. Balaspiri, 1976 .

Neuroanatomical distribution and function of the vasopressin V1B receptor in the rat brain deciphered using specific fluorescent ligands.

G. Guillon, M. Manning, Y. Ueta, 2017, General and comparative endocrinology.

Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies.

M. Manning, B. Mouillac, T. Durroux, 2008, Mini reviews in medicinal chemistry.

Immunochemical studies of myoglobin with synthetic peptides.

M. Manning, A. Sehon, J. K. Givas, 1972, Biochemistry.

Isolation of antibodies to the C-terminal heptapeptide of myoglobin with a synthetic peptide.

M. Manning, A. Sehon, E. R. Centeno, 1968, Immunochemistry.

Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.

N. Cotte, E. Mahé, M. Manning, 2000, European journal of biochemistry.

Design of cyclic and linear peptide antagonists of vasopressin and oxytocin: current status and future directions

M. Manning, W. H. Sawyer, W. Y. Chan, 1993, Regulatory Peptides.

Selective and Potent Agonists and Antagonists for Investigating the Role of Mouse Oxytocin Receptors

M. Manning, G. Kleinau, B. Chini, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Synthesis and Receptor Specificities of Vasopressin Antagonists

M. Manning, W. H. Sawyer, 1986, Journal of cardiovascular pharmacology.

Natriuretic effect of [7-glycine]oxytocin in the presence of diuretic agents in conscious rats.

M. Manning, W. H. Sawyer, C. Stier, 1980, The Journal of pharmacology and experimental therapeutics.

An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acidsSymbols and abbreviations are in accordance with the recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature (Eur. J. Biochem. 180, A9-A11, 1989)

S. Stoev, M. Manning, A. Olma, 1999 .

Design and Characterization of Superpotent Bivalent Ligands Targeting Oxytocin Receptor Dimers via a Channel-Like Structure.

S. Stoev, M. Manning, T. Bellini, 2016, Journal of medicinal chemistry.

Vasopressin and oxytocin receptors in GtoPdb v.2023.1

G. Gimpl, J. Verbalis, D. Bichet, 2023, IUPHAR/BPS Guide to Pharmacology CITE.

Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.

S. Stoev, M. Manning, W. Y. Chan, 2009, International journal of peptide and protein research.

Characterization of a uterine-type oxytocin receptor in the rat hippocampus.

M. Mühlethaler, J. Dreifuss, M. Manning, 1983, Proceedings of the National Academy of Sciences of the United States of America.

2-O-alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: highly specific and potent antidiuretic agonists.

M. Manning, A. Misicka, W. Sawyer, 1989, Journal of medicinal chemistry.

Design of neurohypophyseal peptides that exhibit selective agonistic and antagonistic properties.

M. Manning, W. H. Sawyer, J. Lowbridge, 1977, Federation proceedings.

Functional architecture of vasopressin/oxytocin receptors.

J Hoflack, N. Cotte, S. Trumpp-Kallmeyer, 1999, Journal of receptor and signal transduction research.

Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.

S. Stoev, M. Manning, B. Mouillac, 2002, Journal of medicinal chemistry.

4-Threonine-Oxytocin: A More Active and Specific Oxytocic Agent than Oxytocin

M. Manning, W. Sawyer, 1970, Nature.

The Discovery of Novel Vasopressin V1b Receptor Ligands for Pharmacological, Functional and Structural Investigations

C. S. Gal, G. Guillon, S. Stoev, 2004, Journal of neuroendocrinology.

Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin.

S. Stoev, M. Manning, A. Misicka, 1990, Journal of medicinal chemistry.

A Novel Approach to the Design and Synthesis of Radio-Iodinated Linear Antagonists of Vasopressin and Oxytocin,

M. Manning, S. Audigier, C. Barberis, 1992 .

Design of more potent and selective antagonists of the antidiuretic responses to arginine-vasopressin devoid of antidiuretic agonism.

M. Manning, A. Olma, W. Sawyer, 1982, Journal of medicinal chemistry.

DESIGN OF MORE POTENT AND SELECTIVE ANTAGONISTS OF THE ANTIDIURETIC RESPONSES TO ARGININE-VASOPRESSIN DEVOID OF ANTIDIURETIC AGONISM

M. Manning, A. Olma, W. Sawyer, 1982 .

[Treatment of diabetes insipidus with synthetic vasopressin derivatives (effect of 1-deamino-8-D-arginine vasopressin and 1-deamino-valine-8-D-arginine vasopressin)].

M. Manning, L. Czakó, F. László, 1980, Orvosi Hetilap.

Probing the Existence of G Protein-Coupled Receptor Dimers by Positive and Negative Ligand-Dependent Cooperative Binding

Maurice Manning, Christophe Breton, J. Pin, 2006, Molecular Pharmacology.

Experimental uses of neurohypophysial hormone analogs

M. Manning, W. Sawyer, 1989, Trends in Endocrinology & Metabolism.

18 – Vla Vasopressin Receptors: Studies with Radioiodinated Ligand

M. Manning, T. Durroux, S. Audigier, 1993 .

Highly potent and selective Tyr-NH2 9-containing linear V1 antagonists and D-Tyr2-containing linear V2 agonists: Potential radioiodinated ligands for vasopressin receptors

S. Stoev, M. Manning, W. Sawyer, 1991 .

Iodination of vasopressin analogues with agonistic and antagonistic properties: effects on biological properties and affinity for vascular and renal vasopressin receptors.

R. Seyer, M. Manning, A. Aumelas, 1987, Molecular pharmacology.

Discovery of Novel Selective Hypotensive Vasopressin Peptides

S. Stoev, M. Manning, W. Y. Chan, 1998 .

Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.

M. Manning, A. Olma, W. Sawyer, 1995, Journal of medicinal chemistry.

NONOSMOTIC RELEASE AND VASCULAR EFFECTS OF VASOPRESSIN

D. Schreier, M. Manning, J. P. Goldberg, 1981 .

Synthesis and Some Pharmacological Properties of [4-Threonine,7-glycine]oxytocin,[1-(L-2-Hydroxy-3-mercaptopropanoic acid),4-threonine, 7-glycine]oxytocin (Hydroxy[Thr4,Gly7]oxytocin), and [7-Glycine]oxytocin, Peptides with High Oxyto

M. Manning, W. Sawyer, J. Lowbridge, 1977 .

Identification of a Single Residue Responsible for Agonist Selectivity in the Oxytocin‐Vasopressin Receptors

M. Manning, B. Mouillac, J. Hoflack, 1997 .

Elasmobranch oxytocin-like principles: comparisons with synthetic glumitocin.

M. Manning, W. Sawyer, E. Heinicke, 1969, General and comparative endocrinology.